Literature DB >> 16188549

Clinical applications of BMPs.

Pietro De Biase1, Rodolfo Capanna.   

Abstract

Bone morphogenetic proteins (BMPs) are polypeptides discovered by Marshall Urist in 1965 and later defined by his co-workers as multifunctional cytokines involved in osteoinduction. They are members of the transforming growth factor-beta superfamily with the exception of the BMP-1. Till now at least 20 BMPs have been identified and studied, but only BMP 2, 4 and 7 have been able in vitro to stimulate the entire process of stem cell differentiation into osteoblastic mature cells. After in vitro studies BMPs have been tested in preclinical and clinical studies, showing their definite potential in osteoinduction and have been approved for clinical use in open fracture of long bones, non-unions and vertebral arthrodesis. But more clinical use of these molecules is under investigation and the possibility of using gene therapy in selected pathologies seems the most appealing.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16188549     DOI: 10.1016/j.injury.2005.07.034

Source DB:  PubMed          Journal:  Injury        ISSN: 0020-1383            Impact factor:   2.586


  27 in total

Review 1.  Molecular targets for tendon neoformation.

Authors:  Hadi Aslan; Nadav Kimelman-Bleich; Gadi Pelled; Dan Gazit
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

Review 2.  Gene therapy approaches to regenerating bone.

Authors:  Nadav Kimelman Bleich; Ilan Kallai; Jay R Lieberman; Edward M Schwarz; Gadi Pelled; Dan Gazit
Journal:  Adv Drug Deliv Rev       Date:  2012-03-10       Impact factor: 15.470

3.  Bone morphogenetic protein 9 overexpression reduces osteosarcoma cell migration and invasion.

Authors:  Zilan Lv; Dandan Yang; Jie Li; Min Hu; Min Luo; Xiaoqin Zhan; Peipei Song; Chen Liu; Huili Bai; Baolin Li; Yang Yang; Yingying Chen; Qiong Shi; Yaguang Weng
Journal:  Mol Cells       Date:  2013-06-25       Impact factor: 5.034

Review 4.  The potential impact of bone tissue engineering in the clinic.

Authors:  Ruchi Mishra; Tyler Bishop; Ian L Valerio; John P Fisher; David Dean
Journal:  Regen Med       Date:  2016-08-23       Impact factor: 3.806

5.  An alginate-based hybrid system for growth factor delivery in the functional repair of large bone defects.

Authors:  Yash M Kolambkar; Kenneth M Dupont; Joel D Boerckel; Nathaniel Huebsch; David J Mooney; Dietmar W Hutmacher; Robert E Guldberg
Journal:  Biomaterials       Date:  2010-09-22       Impact factor: 12.479

Review 6.  Infection and tissue engineering in segmental bone defects--a mini review.

Authors:  Manitha B Nair; James D Kretlow; Antonios G Mikos; F Kurtis Kasper
Journal:  Curr Opin Biotechnol       Date:  2011-02-25       Impact factor: 9.740

Review 7.  How does the pathophysiological context influence delivery of bone growth factors?

Authors:  Xiaohua Yu; Darilis Suárez-González; Andrew S Khalil; William L Murphy
Journal:  Adv Drug Deliv Rev       Date:  2014-10-17       Impact factor: 15.470

8.  Spatiotemporal delivery of bone morphogenetic protein enhances functional repair of segmental bone defects.

Authors:  Yash M Kolambkar; Joel D Boerckel; Kenneth M Dupont; Mehmet Bajin; Nathaniel Huebsch; David J Mooney; Dietmar W Hutmacher; Robert E Guldberg
Journal:  Bone       Date:  2011-05-18       Impact factor: 4.398

9.  Growth Factor Dose Tuning for Bone Progenitor Cell Proliferation and Differentiation on Resorbable Poly(propylene fumarate) Scaffolds.

Authors:  Ruchi Mishra; Ryan S Sefcik; Tyler J Bishop; Stefani M Montelone; Nisha Crouser; Jean F Welter; Arnold I Caplan; David Dean
Journal:  Tissue Eng Part C Methods       Date:  2016-09       Impact factor: 3.056

10.  BMP2 cross-linked by transglutaminase 2 to collagen-plla scaffold promotes osteogenic differentiation in mesenchymal stem cells.

Authors:  Kelly E Beazley; Maria Nurminskaya
Journal:  Biotechnol Lett       Date:  2014-06-15       Impact factor: 2.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.